Xigris worked, so why did Lilly withdraw the drug?

The clinical trial that caused Eli Lilly abruptly to withdraw its septic shock treatment Xigris (drotrecogin alfa [activated]) from all markets in October 2011 (scripintelligence.com, 27 October 2011) may have been flawed, or at least atypical of clinical practice, according to a recent meta-analysis of Xigris studies.